Our findings indicate that outlier expression of SMC4 exhibit a robust prognostic association with metastatic progression, and that the SMC4 prognostic outlier genes continue to occupy roles in metastatic prostate cancer. This evidence concerns the gene SMC4 and metastatic prostate carcinoma.